USANA Health Sciences (NYSE:USNA) Releases Quarterly Earnings Results

USANA Health Sciences (NYSE:USNA) posted its quarterly earnings data on Tuesday. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07, Yahoo Finance reports. The business had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. During the same period last year, the company earned $0.59 earnings per share. USANA Health Sciences updated its FY 2024 guidance to 2.450-2.450 EPS.

USANA Health Sciences Stock Up 3.2 %

Shares of NYSE:USNA traded up $1.10 during mid-day trading on Wednesday, reaching $35.58. 11,590 shares of the stock were exchanged, compared to its average volume of 79,591. The company has a market cap of $677.83 million, a P/E ratio of 10.55, a P/E/G ratio of 1.20 and a beta of 0.89. USANA Health Sciences has a one year low of $34.15 and a one year high of $55.45. The stock’s 50 day simple moving average is $38.02 and its 200-day simple moving average is $42.59.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on USNA. DA Davidson decreased their price objective on USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating for the company in a report on Wednesday. StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th.

Insider Buying and Selling

In related news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total transaction of $240,489.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director John Turman Fleming sold 1,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the transaction, the director now directly owns 2,503 shares of the company’s stock, valued at approximately $111,208.29. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Paul A. Jones sold 6,266 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 7,940 shares of company stock worth $311,670. 0.33% of the stock is owned by corporate insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.